Flow cytometry analysis showed an increase in the percentages of non-classical (CD14+CD16++) and intermediate monocytes (CD14++CD16+) at the expense of classical monocytes (CD14++CD16–) in MS patients (Figure 1B). Here, CD14 is linked to myeloid sarcoma.